Fig. 4From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanACR20 response at each visit by maximum peficitinib dose level (FAS). *Includes LOCFBack to article page
